Results 111 to 120 of about 30,003 (287)

Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort [PDF]

, 2016
Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking.
Balázs Szalay, Barbara D. Lovász, Best, Beáta Gasztonyi, Ferenc Nagy, Gábor T. Tóth, János Banai, Klaudia Farkas, Krisztina B. Gecse, Károly Palatka, Lilla Lakner, László Bene, László Lakatos, Mária Papp, Márk Juhász, Petra Anna Golovics, Péter L. Lakatos, Tamás Molnár, Tamás Szamosi, Tünde Kristóf, Zoltán Szepes, Ágnes Anna Csontos, Ágnes Salamon, Áron Vincze, Árpád Patai   +24 more
core   +3 more sources

CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Allergy, EarlyView.
This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan   +16 more
wiley   +1 more source

Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis

ACR Open Rheumatology, 2020
Objective Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce ...
Zachary S. Wallace, Tyler Harkness, Kimberly G. Blumenthal, Hyon K. Choi, John H. Stone, Rochelle P. Walensky   +5 more
doaj   +1 more source

Pharmacogenetics of follicle‐stimulating hormone action in the male

Andrology, EarlyView.
Abstract Male factor infertility (MFI) is involved in half of the cases of couple infertility. The follicle‐stimulating hormone (FSH) therapy is considered efficient to improve semen parameters and pregnancy rate in patients with idiopathic MFI, following the lesson learned from hypogonadotropic hypogonadism.
Andrea Graziani, Giuseppe Grande, Raffele Scafa, Riccardo Selice, Andrea Garolla, Maria Santa Rocca, Cinzia Vinanzi, Alberto Ferlin   +7 more
wiley   +1 more source

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. [PDF]

, 2019
Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX ...
DeHoratius, Raphael J., Ellis, Lorie A., Kafka, Shelly, Kubacki, Maureen, Malangone-Monaco, Elisabetta, Stetsovsky, Diana, Varker, Helen   +6 more
core   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, EarlyView.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.

PLoS ONE
BackgroundBiosimilars have the potential to save a significant amount of money in cancer treatment costs. However, barriers exist in the adoption of biosimilar products.
Hisashi Itoshima, Daisuke Takada, Etsu Goto, Noriko Sasaki, Susumu Kunisawa, Yuichi Imanaka   +5 more
doaj   +1 more source

PMS62 A Multi-Country Physician Survey On Patient Eligibility And Use Of Biologics In Rheumatoid Arthritis (Ra), Ankylosing Spondylitis (As) And Psoriatic Arthritis (Psa) In European Union (Eu) [PDF]

, 2013
Item does not contain ...
Narayanan, S., Lu, Y., Hutchings, R., Baskett, A.   +3 more
core   +1 more source

Biosimilars: How similar or dissimilar are they? (Review Article) [PDF]

, 2006
Simon D. Roger
openalex   +1 more source

Meta‐Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
There is uncertainty about the relative efficacy of subcutaneous (SC) compared to intravenous (IV) infliximab in inflammatory bowel disease (IBD). In this network meta‐analysis, SC infliximab was associated with high efficacy rates in IBD use, with a suggestion of clinical benefit above the IV formulation.
John David Chetwood, Arteen Arzivian, Yvonne Tran, Sudarshan Paramsothy, Rupert W. Leong   +4 more
wiley   +1 more source